Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| GE Healthcare | INDUSTRY |
When older patients develop cognitive problems - like memory loss - there may be any of several underlying causes, sometimes occurring in combination. Clinicians have a better chance of providing appropriate treatment if they understand what the cause of the problem is. A diagnostic tool can help the patient by helping the clinician to make a more accurate diagnosis. This study investigates whether a new diagnostic tool - beta amyloid imaging - may potentially improve medical practice. The tool can potentially improve practice only if it can influence clinical judgment. This study investigates whether the provision of beta amyloid imaging information influences clinical judgment. The investigators will conduct a survey that presents clinicians with descriptions of hypothetical older patients with cognitive complaints. Some of the respondents also receive beta amyloid imaging information. The investigators will test the investigators hypothesis that the information will affect diagnostic judgment and management recommendations by comparing the responses of clinicians who receive the beta amyloid information to the responses of clinicians who do not.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Positive beta amyloid findings | Experimental | Beta amyloid imaging results indicated a positive finding. |
|
| Negative beta amyloid findings | Experimental | Beta amyloid imaging results indicated a negative finding. |
|
| No beta amyloid information | No Intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Beta amyloid imaging | Device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss | Proportion of respondents who identify Alzheimer's Disease as the sole or a contributing factor that is responsible for the patient's cognitive complaint. | Online Survey - completion during the estimated 2-3 month field period |
| Likelihood of Recommending a Medication Indicated for Alzheimer's Disease | Proportion of respondents who recommend a medication indicated for the treatment of Alzheimer's Disease, including Acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, Typical antipsychotics - e.g., Chlorpromazine (Thorazine), Haloperidol (Haldol), Atypical antipsychotics - e.g., Clozapine (Clozaril), Risperidone (Risperdal), Antidepressant - e.g., Citalopram (Celexa), Venlafaxine (Effexor), Antianxiety agent - e.g. Benzodiazepines, Buspirone (Buspar). | Online Survey - completion during the estimated 2-3 month field period |
| Likelihood of Recommending That Spouse Take Various Cognitive Deficit Disease Management Measures | Proportion of respondents who recommend that the patient's spouse take actions that would be appropriate if the patient has Alzheimer's disease, including: (1) discussion of advance care planning, (2) monitoring of patient's finances, (3) assessment of how compatible the patient's job is with his conditions, (4) the initiation of precautions to ensure the patient is properly taking his medications to manage hypertension and hyperlipidemia. | Online Survey - completion during the estimated 2-3 month field period |
Not provided
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joshua T. Cohen, Ph.D | Tufts Medical Center | Study Director |
| Peter J Neumann, ScD | Tufts Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tufts Medical Center | Boston | Massachusetts | 02111 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Positive Beta Amyloid Findings | Beta amyloid imaging results indicated a positive finding. Beta amyloid imaging |
| FG001 | Negative Beta Amyloid Findings | Beta amyloid imaging results indicated a negative finding. Beta amyloid imaging |
| FG002 | No Beta Amyloid Information |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
number of clinicians responded to the email
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Positive Beta Amyloid Findings | Survey respondents presented scenario in which beta amyloid imaging results indicated a positive finding. |
| BG001 | Negative Beta Amyloid Findings |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Baseline characteristics are reported by subject. |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss | Proportion of respondents who identify Alzheimer's Disease as the sole or a contributing factor that is responsible for the patient's cognitive complaint. | Posted | Number | participants | Online Survey - completion during the estimated 2-3 month field period |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Positive Beta Amyloid Findings | Beta amyloid imaging results indicated a positive finding. Beta amyloid imaging |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr.Yue Zhong, Project Director of Center for the Evaluation of Value and Risk in Health | Tufts Medical Center | 6176361424 | yzhong@tuftsmedicalcenter.org |
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D060825 | Cognitive Dysfunction |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Survey respondents presented scenario in which beta amyloid imaging results indicated a negative finding.
| BG002 | No Beta Amyloid Information | Survey respondents presented scenario with no beta amyloid information. |
| BG003 | Total | Total of all reporting groups |
| Mean |
| Standard Deviation |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Beta Amyloid imaging findings | Number | participants |
|
| OG002 |
| No Beta Amyloid Information |
|
|
| Primary | Likelihood of Recommending a Medication Indicated for Alzheimer's Disease | Proportion of respondents who recommend a medication indicated for the treatment of Alzheimer's Disease, including Acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, Typical antipsychotics - e.g., Chlorpromazine (Thorazine), Haloperidol (Haldol), Atypical antipsychotics - e.g., Clozapine (Clozaril), Risperidone (Risperdal), Antidepressant - e.g., Citalopram (Celexa), Venlafaxine (Effexor), Antianxiety agent - e.g. Benzodiazepines, Buspirone (Buspar). | Posted | Number | participants | Online Survey - completion during the estimated 2-3 month field period |
|
|
|
| Primary | Likelihood of Recommending That Spouse Take Various Cognitive Deficit Disease Management Measures | Proportion of respondents who recommend that the patient's spouse take actions that would be appropriate if the patient has Alzheimer's disease, including: (1) discussion of advance care planning, (2) monitoring of patient's finances, (3) assessment of how compatible the patient's job is with his conditions, (4) the initiation of precautions to ensure the patient is properly taking his medications to manage hypertension and hyperlipidemia. | Posted | Number | participants | Online Survey - completion during the estimated 2-3 month field period |
|
|
|
| 0 |
| 106 |
| 0 |
| 106 |
| EG001 | Negative Beta Amyloid Findings | Beta amyloid imaging results indicated a negative finding. Beta amyloid imaging | 0 | 105 | 0 | 105 |
| EG002 | No Beta Amyloid Information | 0 | 104 | 0 | 104 |
Not provided
Not provided
| D024801 |
| Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D003072 | Cognition Disorders |